Theratechnologies:
Clinically Poised for High Growth Opportunities

NASDAQ: **THTX**
TSX: **TH**

June 2022

Forward-Looking Information

The following presentation contains statements that are considered forward-looking information (“FLI”) within the meaning of securities regulation.

The FLI in this presentation relates to future events or our future performance. The FLI are based on a number of assumptions and are associated with a number of risks, uncertainties and other unknown factors that may cause our actual results, levels of activity, performance or achievements to be materially different from those implied by the FLI.

Such FLI reflects our current views with respect to future events and is given as of **June 15, 2022**. We undertake no obligation and do not intend to update or revise the FLI contained in this presentation, except as required by law.

Certain assumptions made in preparing the FLI include, but are not limited to, the following:

- (1) Global trade and supply issues will have limited adverse effects on our activities and business plan;
- (2) sales of *EGRIFTA SV*® and Trogarzo® will continue to grow in the United States;
- (3) the known safety and efficacy profile of *EGRIFTA* SV® and Trogarzo® will not change as a result of their long-term use;
- (4) the FDA will approve the sBLA related to the IV Push mode of administration of Trogarzo®;
- (5) the FDA will approve the F8 formulation of tesamorelin, once an sBLA has been filed;
- (6) we will succeed in developing a multi-dose injection pen using the F8 formulation and regulatory agencies will approve same;
- (7) no biosimilar version of *EGRIFTA SV*® will be approved by the FDA;
- (8) we will be able to secure additional resources to initiate our Phase 3 clinical trial evaluating tesamorelin for the treatment of NASH, including finding a partner;
- (9) the totality of evidence and data resulting from the conduct of our planned Phase 2b/3 clinical trial evaluating tesamorelin for the treatment of NASH will demonstrate substantial evidence of efficacy and will be highly persuasive to regulatory agencies in order to gain approval;
- (10) we will obtain positive results from our Phase 1 clinical trial evaluating TH1902 for the treatment of various cancers; and,
- (11) we will meet all of the timelines set forth in this presentation.

The FLI in our presentations may not materialize; accordingly, investors should not place undue reliance on it. We refer you to the “Forward-Looking Information” section of our Management’s Discussion and Analysis dated February 23, 2022 and to the “Risk Factors” section of our Annual Information Form dated February 23, 2022. These documents are available at **www.sedar.com** and as exhibits to our Form 40-F dated February 24, 2022 available on Edgar at **www.sec.gov** for a description of the risks related to the conduct of our business.

Theratechnologies (NASDAQ:THTX; TSX:TH)

Corporate Profile

- **Founded in 1993 in Montreal, Canada**, Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs
- **Incorporated in Quebec,** with primary offices in Montreal, subsidiary locations in Dublin, Ireland, and the United States
- The company has approximately ~**165 employees*** across Canada, the United States and Europe
- Dual listed on the Nasdaq Stock Exchange under ticker **(NASDAQ:THTX)** since 2019 and the Toronto Stock Exchange under ticker **(TSX:TH)** since 1993

Stock Information

• Stock Price (as of 6/15/22)	**$2.34**
• Shares Outstanding (as of 6/15/22)	**~95M**
• Market Cap (as of 6/15/22)	**~$223M**
• Cash, cash equivalents (as of 2/28/22)	**~$34M**
• Convertible notes outstanding (5.75% coupon; due 6/30/23; $14.85 conversion price)	**$57.5M**

Notes:
**Full-time employees and dedicated third parties*
$ values in USD

Promising R&D Pipeline and Commercial Portfolio

Promising R&D Pipeline

Novel therapies in Oncology, NASH, and HIV

- Phase 1 trial initiated in sortilin-expressing cancers
- NASH in non-HIV and HIV populations
- Next-generation administration method for Trogarzo® and new formulation of tesamorelin

Two Commercially Approved Therapies

Improving standard of care for people living with HIV

- Trogarzo® for multidrug resistant (MDR) HIV-1 in adults
- *EGRIFTA SV*® for HIV-associated lipodystrophy



Oncology, NASH and HIV R&D Pipeline

Notes:
- *Clinical study for Trogarzo IV Push was conducted by TaiMed Biologics, Inc.*
- *Clinical study for Trogarzo Intramuscular (IM) is being conducted by Theratechnologies*

THERA technologies

Oncology:
SORT1+ Technology™

SORT1+ Technology™: First-in-Class Peptide Drug Conjugate (PDC) Platform Targeting Sortilin (SORT1) Receptors for Cancer

Targets SORT1, a novel receptor that is highly expressed in many types of cancer and is associated with poor prognosis and decreased survival.

Rapid internalization leading to high cytotoxic concentration inside the cancer cells for improved efficacy, safety, and durable response.

Overcomes two key resistance mechanisms: Bypasses the MDR1 efflux pump and inhibits vasculogenic mimicry (VM) formation.

TH1902 is the lead **PDC** and is currently in Phase 1 clinical development. FDA has granted **fast track designation** for TH1902 to be developed as a **single agent** for treatment of patients with **SORT1+ recurrent advanced solid tumors** that are **refractory to standard therapy.**

Source: Seyfried TN et al. Crit Rev Onc. 2013; 18(1-2):43–73.

The SORT1 Receptor Is an Attractive Novel Target for Cancer Therapy

SORT1

Key receptor used by cancer cells that:

1. Is highly expressed in many cancer cells compared to normal healthy cells
2. Normal function is to transport proteins across cell membrane
3. Leads to aggressive behavior (cancer progression and invasion), metastases, and poor survival
4. By targeting SORT1, can bypass MDR1 efflux pump and inhibit vasculogenic mimicry (VM) formation - two key resistance mechanisms



Sources: Annabi B et al. AACR 2020, Abstract #4386.; Demeule M et al. AACR 2020, Abstract #4335. .

SORT1 is Highly Expressed in Cancer Cells Compared to Normal Cells

Attractive target: As cancer aggressiveness increases, SORT1 expression increases[1]



Metastatic lymph node from breast carcinoma



Infiltrating ductal carcinoma of breast



Normal adjacent breast tissue

Affects outcomes: High SORT1 gene expression is associated with decreased survival[2]



TNBC, triple-negative breast cancer

Source: Demeule M et al. AACR 2020, Abstract #4335.2. Currie JC et al. AACR 2020, Abstract #4472. i

SORT1 Staining in Small Cell Lung Cancer

Normal Tissue



Small Cell Lung Cancer



STAINING

SORT1: **brown** Nucleus: **blue**

Source: Theratechnologies, Data on File.

TH1902: Lead PDC Using Theratechnologies' Exclusive SORT1+ Technology™

Peptide[1,2]

- Targets **SORT1** receptor, expressed in multiple cancers
- Can be conjugated to variety of anti-cancer agents with consistent number of payload molecules
- Provides **rapid internalization** and delivery of payload inside the cell, limiting degradation in the circulation and off target toxicity



Cytotoxic payload[2-4]

- For TH1902 is **docetaxel (2:1 ratio)**, a well-established agent for a variety of cancers with known safety profile
- **Increases therapeutic window of docetaxel**
  - Use smaller dose to get greater efficacy and less toxicity (neutropenia)

Cleavable linker[2,3]

- Links the SORT1-targeting peptide to the cytotoxic docetaxel
- Increased stability in plasma with improved distribution into targeted cancer cells
- Enables rapid release of docetaxel inside the cancer cell

Notes:
1) *Annabi B et al. AACR 2020, Abstract #4386.*
2) *Hoppenz P et al. Front Chem. 2020; 8: 571.*
3) *Currie JC et al. AACR 2020, Abstract #4472.*
4) *Zhang E et al. Expert Opin Drug Deliv. 2019 Mar;16(3):301-31.*

TH1902: Delivering Cancer-Killing Docetaxel Directly Into Cancer Cells



Sources: Demeule M et al. AACR 2020, Abstract #4335.; Makawita S, Meric-Bernstam F. Am Soc Clin Oncol Educ Book. 2020 Mar;40:1-10.; Taxotere (docetaxel Prescribing Information. Bridgewater, NJ: Sanofi-Aventis U.S. LLC.; May 2020).

SORT1+ Technology™: Potentially Increased Efficacy in Refractory/Resistant Tumors (bypass of MDR1 pump)

MDR1 efflux pump is often used by cancer cells to resist treatment

When MDR1 is inhibited:



MDR1 bypass allows the PDC to accumulate in tumor cells (B) to a greater extent than the cytotoxic alone (A)



TH1902, docetaxel peptide conjugate; CsA, cyclosporin A
Source: Theratechnologies, Data on File.

Theratechnologies' PDC's Inhibit Vasculogenic Mimicry – A Key Survival Mechanism for Some Tumors

- Cancer cells need blood, nutrients and oxygen to sustain growth and cell division
- This is achieved by either forming new blood vessels **(angiogenesis)** or by forming new channels lined with cancer cells that extend from the existing vasculature - a process called **vasculogenic mimicry (VM)**
- VM is SORT1-dependent and is associated with cancer resistance and aggressive disease

Normally blood flow is provided by blood vessels, lined by endothelial cells.



With VM, the channels are lined with tumor cells.



Preliminary pre-clinical data using SORT1+ Technology™ suggests it can potentially inhibit the formation of VM structures associated with cancer resistance mechanisms

Sources: Demeule M et al. AACR 2020, Abstract #4335.; Gong F-L et al. J Cell Biochem. 2020; 121:4756-4771.; Sun B et al. Oncotarget. 2017;8(18):30502-30510

TH1902 Demonstrates Improved Tolerability in Pre-clinical Models

Minimal docetaxel released in blood further limiting off-target toxicity



Source: Currie JC et al. AACR 2020, Abstract #4472.

TH1902 Sustains Reductions in Breast Cancer Tumor Burden Over Time (Pre-clinical Model)



Purple arrows: 3 cycles of docetaxel or TH1902 treatment
Green arrows: 2 additional cycles of TH1902

Source: Demeule M et al. AACR 2021, Abstract #1313; TNBC s.c. xenograft tumor models

TH1902: Pre-clinical Data in Pancreatic Cancer

Low Doses



Docetaxel at MTD



Source: Demeule M et al. AACR 2021, Abstract #1313; Pancreatic (PANC-1) s.c. xenograft tumor model

TH1902: Pre-clinical Data in Endometrial Cancer



Source: Demeule M et al. AACR 2021, Abstract #1313; Endometrial (HT-29) s.c. xenograft tumor model

TH1902: Pre-clinical Data in Melanoma



Purple arrows: 3 cycles of docetaxel or TH1902 treatment
Green arrows: 3 additional cycles of TH1902 treatments at ½ the starting dose (17.5mg/kg)

Source: Demeule M et al. AACR 2021, Abstract #1313.;l Melanoma (SK-MEL-28) s.c. xenograft tumor model

Phase 1/Part B Trial of TH1902 Underway

Multi-center, open-label trial

FDA Fast Track Designation Granted

Part A: Dose Escalation

Advanced solid tumors relapsed/ refractory to standard therapy/no known effective therapies exist **(all comers) (n=15-25)**

USA only

30 mg/m² TH1902

420 mg/m2 had 1 DLT of neutropenia and other toxicity Decreased to 300 mg/m2 and expanded to 3 pts

Intra-patient dose escalation scheme until **max tolerated dose (MTD)** is reached[1]

Part B: Basket trial

SORT1+ patients with:

- HR+ BC (n=10)
- TNBC[2] (n=10)
- Endometrial cancer (n=10)
- Ovarian cancer (n=10)
- Melanoma (n=10)
- Thyroid (n=5) SCLC[2] (n=5) Prostate (n=5) Others (n=5-10)

USA and Europe

Recommended phase 2 dose (RP2D)[3] TH1902

- Safety
- Tolerability
- Preliminary anti-tumor activity

Notes:
[1] If ≥2 patients in a dose cohort experience an emergent DLT by Day 21 of the first treatment cycle, dose escalation will stop, and the prior dose level will be declared as the MTD. MTD is defined as highest dose level at which ≤1 of 6 patients in a cohort develop an emergent dose-limiting toxicity;
[2]As indicated; TNBC, triple-negative breast cancer; SCLC, Small Cell Lung Cancer
[3]RP2D is defined as one dose level below the MTD and is the recommended phase 2 dose to further assess TH1902 for safety/tolerability and preliminary anti-tumor activity

Phase 1 Clinical Trial: Dose Escalation And Basket Trial Design



Notes:
[1]Patients 6 and 7 did not complete Cycle 1 and thus were considered as not evaluable.
[2]Currently evaluated dose

TH1902 Phase 1/Part B Basket Study Initiated

- Phase 1/Part B dose established at 300 mg/m2 or 1.5 times the therapeutic dose of docetaxel alone.
- No dose limiting toxicities were observed following the completion of the first cycle in the last 6 patients treated at 300 mg/m2.
- Expansion study will evaluate TH1902 as a monotherapy in solid tumors with high expression of Sortilin receptor, including Hormone Receptor-positive (HR+) Breast Cancer, Triple Negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, and Melanoma with approximately 10 patients per tumor type.
- One arm will include a mix of tumor types including Thyroid, Small Cell Lung, Prostate and potential other high Sortilin expressing cancers with approximately 15 patients in total. In addition to evaluating the anti-tumor activity of TH1902, the study will continue to evaluate the safety and pharmacokinetics of TH1902.

SORT1+ Technology™: Future Opportunities

- Explore different **dosing schedules** (weekly, intermittent vs continual) in order to **increase the therapeutic window** in terms of efficacy and safety.
- Gain better understanding of the exact **MOA, impact on surrounding tissue/tumor microenvironment (TME)** and **fate of conjugate** once it enters the cell and is degraded.
- Explore **conjugation with a variety of anti-cancer agents** (cytotoxics, TKIs etc) and potential synergistic new partnerships (proprietary molecules).
- Explore **rational combinations** of SORT1+ Technology™ with other treatments, especially immunotherapies.
- Explore the need for a **companion diagnostic** for SORT1 to determine correlation of sortilin expression with response, improve patient selection, track treatment efficacy and identify early metastases.

THERA technologies

General and HIV-Associated NASH: *Tesamorelin*

Tesamorelin: A Growth Hormone Releasing Hormone (GHRH) Targeting the Underlying Mechanisms of NASH

❶ Direct effect:
Tesamorelin stimulates endogenous production of GH

- ✓Reduces visceral fat
- ✓Decreases lipogenesis
- ✓Decreases triglyceride accumulation
- ✓Decreases oxidative stress and inflammation
- ✓Improves mitochondrial function

Decreases fat toxicity

❷ Indirect effect:
GH stimulates endogenous production of IGF-1 in the liver

- ✓Decreases insulin resistance
- ✓Decreases oxidative stress and inflammation
- ✓Deactivates hepatic stellate cells (liver cells that contribute to fibrosis)

Decreases hepatocyte injury and fibrosis



GH (growth hormone); GHRH (growth hormone-releasing hormone); IGF-1 (Insulin-like growth factor 1); NASH (nonalcoholic steatohepatitis)

Sources: Xu and al., PLOS one, 2012: 7(8): e44136.; Takahashi et al., International Journal of Molecular Sciences, 2017: 18: 1446.; Fourman et al., JCI Insight, 2020: 5(16): e140134.; Connolly, J Clin Transl Hepatol 2018. ***5.*** *Liu Z et al. Diabetes. 2016 Dec;65(12):3598-3609.*

Effects of Tesamorelin in HIV NAFLD/NASH Patients [1]

Baseline Characteristics

- 61 men and women with HIV infection
- Hepatic fat levels of 13.8%
- 43% of patients had fibrosis
- 33% of patients had NASH (score 2.7)
- Study discontinuation: 14 patients
- Without biopsies
  - 3 patients at baseline
  - 18 patients at year 1

(37%) Treatment Effect vs. Placebo



>30% Liver Fat Reduction in Significant Proportion of Patients



Liver Fat Normalization



Delayed Progression of Fibrosis



Tesamorelin Placebo

Sources:
(1) Investigator-Initiated Study (Stanley et al., Effects of Tesamorelin on Non-Alcoholic Fatty Liver Disease in HIV; A Randomised, Double-Blind, Multicentre Trial. The Lancet HIV. 2019;6(12): E821-E830.
(2) Patel J, Bettencourt R, Cui J, et al. Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis. Therap Adv Gastroenterol. 2016;9(5):692-701.
(3) Stine JG et al. Clin Gastroenterol Hepatol. 2020 Aug 31;S1542-3565(20)31220-9.
(4) Tamaki et al. Gut. 2021.

U.S. Market Represents a Significant and Growing Opportunity in NASH



Sources: Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67(1):123-133. doi:10.1002/hep.29466.; Wall Street consensus forecast figures based on Intercept and Madrigal, and company estimates

Update on Tesamorelin Development Pathway in NASH

- Discussions with FDA and EMA are **complete**
- Phase 3 clinical trial **design finalized**
- **Amended trial design** includes a Phase 2b/3 seamless study design where the first 350 patients' data will be analyzed by a data monitoring committee to inform a go/no-go decision to continue the study
- In parallel, exploring other **non-dilutive financing** options and **partnerships** prior to trial initiation

THERA technologies

HIV Therapies:

Trogarzo® (ibalizumab-uiyk)/

EGRIFTA SV® (tesamorelin for injection)

Commercial HIV Portfolio



HIV Franchise – Initiatives Launched

- ✓ Enhance communications of clinical / scientific evidence to close the education gap with providers
- ✓ Develop patient activities to increase understanding of disease progression and benefits of *EGRIFTA SV*®
- ✓ Utilize digital strategies to increase brand awareness among physicians and KOLs

Next-Generation Administration and Delivery

- ✓ **Patient / Prescriber Education:** Targeted educational initiatives to key KOLs, patients and the HIV community
- ✓ **Life Cycle Management:** Multi-dose pen injector in development for tesamorelin F8 formulation; Trogarzo® IV Push study completed and sBLA filed with the FDA; Trogarzo® IM study patient enrollment underway
- ✓ **Continued Commitment:** Providing best-in-class treatments for people living with HIV; HIV patient cohort to be included in Phase 3 NASH trial

Trogarzo® (ibalizumab-uiyk) injection

- **Ibalizumab** - a monoclonal antibody targeting the CD4 receptor
- Indicated for MDR HIV-1 in adults
- Helps people living with HIV to attain an undetectable viral load
  - ***Potency*:** novel mechanism of action that is fully active with no expected cross-resistance
  - ***Durability*:** powerful and durable virologic response
  - ***Long Activity*:** the first and only long-acting ARV
  - ***Simplicity*:** no expected drug-drug interactions and well-established safety profile
- Regulatory exclusivity in the U.S. until March 2030
- sBLA for IV push mode of administration of Trogarzo® filed with FDA; Initiation of patient enrollment for Trogarzo® IM study

Key Highlights

- ✓ First HIV treatment approved with a new mechanism of action in more than 10 years
- ✓ Infused every two weeks, the first and only anti-retroviral therapy (ART) that does not require daily dosing
- ✓ No drug-drug interactions with other ARTs

Notes:
- Most common drug-related adverse reactions include diarrhea, dizziness, nausea and rash
- Clinical study for Trogarzo IV Push was conducted by TaiMed Biologics, Inc.
- Clinical study for Trogarzo Intramuscular (IM) will be conducted by Theratechnologies
- For more information visit www.trogarzo.com

EGRIFTA SV® (tesamorelin for injection)

Key Highlights

- ✓ Single vial with small volume injection at room temperature
- ✓ Unique mechanism of action that regulates growth hormone (GH) secretion
- ✓ Tesamorelin's ability to increase endogenous GH secretion is the foundation for development in NASH

- **Tesamorelin** – a growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to release endogenous GH in a pulsatile way
- Only treatment available for adults with HIV and lipodystrophy that reduces excess visceral abdominal fat
  - ***Specificity***: unique mechanism of action that regulates GH secretion
  - ***Maintained Efficacy***: results shown at week 26 and maintained at week 52 with 27% decrease in visceral abdominal fat
  - ***Simplicity***: a single vial with a small volume of injection storable at room temperature
  - ***Medical Benefit***: left untreated, excess visceral abdominal fat is linked to potential severe health consequences that could lead to an increase risk in mortality
- *EGRIFTA SV*® is expected to drive increased patient compliance
- Well-established safety profile as evidenced by 10+ years of commercial availability with a high degree of tolerability

Notes:

- *Most commonly reported adverse reactions (>5%): Arthralgia, injection site erythema, injection site pruritus, pain in extremity, peripheral edema, and myalgia*
- *For more information visit www.egriftasv.com*

THERA technologies

Business Review

Financial Strength and Stability

$18.5M Q1’22 consolidated commercial sales revenues, +20.3%

$34M Cash and cash equivalents position as of February 28, 2022

$223M Market capitalization with ~95M common shares, ~8.1M warrants and ~5.6M options outstanding (June 15, 2022)

$57.5M Convertible Notes Outstanding: 5.75% Coupon; Due June 30, 2023; $14.85 conversion price

Note: Values in USD millions except share/warrant/option and conversion price data

THERA technologies

Thank You

https://www.theratech.com